Program
Anti-CD32B Monoclonal Antibody BI-1607
Its studies are mostly in Uveal Melanoma · Breast Neoplasms, led by BioInvent International AB.
Furthest: phase 2, since Sep 22, 20222 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioInvent International AB | 21 open or running | phase 2since Sep 22, 2022 | Sep 22, 2022 | none ahead |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2022First study: phase 2 study in HER2-positive Breast CancerFirst studyNCT05555251 · 18 enrolled · Germany, Spain, United Kingdom
- Dec 16, 2024Phase 2 study in MelanomaNCT06784648 · 35 enrolled · Germany, Spain, United Kingdom
TargetBeta
FCGR2B →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody targeting Fc gamma receptor IIB (FcgRIIB; CD32B), ”NCIt, by rule
Other programs on FCGR2B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06784648Melanoma · Germany, Spain, United Kingdom | 2 | Active, not recruiting | Sep 9, 2026 | 35 |
| NCT05555251HER2-positive Breast Cancer · Germany, Spain, United Kingdom | 2 | Terminated | Feb 7, 2024 | 18 |
How it is read
Names in the registry
- “BI-1607”, 3 entries
Conditions, from the studies’ own filings
- Uveal Melanoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.